Gain Therapeutics

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates

HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson's Disease and Movement Disorders ® in Copenhagen, Denmark BETHESDA, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate progress.

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late breaking abstract highlighting the company's lead program, GT-02287, has been accepted for presentation at the upcoming International Congress of Parkinson's Disease and Movement Disorders® to be held August 27-31, in Copenhagen, Denmark.

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson's Disease and Movement Disorders®

BETHESDA, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that members of management will participate in a fireside chat at the 2023 BTIG Virtual Biotechnology Conference on Tuesday, August 8 at 9:30 a.m. ET and host investor meetings.

Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference

BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will present at the Jefferies Healthcare Conference, taking place June 7-9 in New York, NY.

Gain Therapeutics to Present at the Jefferies Healthcare Conference

Gain Therapeutics is a biotechnology company focused on drug development powered by its SEE-Tx™ target identification platform, which identifies and optimizes binding sites on biological targets that have never before been targeted. The company has a potential blockbuster entering a phase 1 clinical trial and several AI drug discovery and gene therapy comps valued in the billions of dollars. Gain Therapeutics is significantly undervalued compared to its competitors, and its management and board, consisting of seasoned biotech entrepreneurs and dealmakers, are expected to maximize the company's value.

Gain Therapeutics: Undervalued Based On Drug Development Platform And Lead Parkinson's Asset

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.28 per share a year ago.

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates

BETHESDA, Md., May 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced financial results for the first quarter ended March 31, 2023, and highlighted recent corporate progress.

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Gain Therapeutics, Inc. (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for

BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the Swiss Innovation Agency, supports GT Gain Therapeutics SA with the amount of CHF 2.5 million (~$2.8 million) to develop GT-02287, Gain's lead program for GBA1 Parkinson's disease.

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's Disease

BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company's Chief Financial Officer, effective immediately. Mr. Ballantyne succeeds Salvatore Calabrese, who is expected to remain employed by the Company for a reasonable transition period to enable an orderly transition of duties.

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

BETHESDA, Md., March 23, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced financial results for the full year ended December 31, 2022, and highlighted recent corporate progress.

Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency

Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program

BETHESDA, Md., March 09, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference, taking place March 14-16 online. Please see additional details below:

Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher disease Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher disease

Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium

BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET.

Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson's Disease Therapeutic, GT-02287

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

Outgoing CEO Eric Richman will continue to serve as a member of the board of directors and serve as a senior advisor to the Company Outgoing CEO Eric Richman will continue to serve as a member of the board of directors and serve as a senior advisor to the Company

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

Presenting Preclinical Data at 2022 International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain

Gain Therapeutics to Present Data at Upcoming Medical Meetings

BETHESDA, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company's Chief Operating Officer, Matthias Alder, will present and host one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14 in New York, NY. Please see additional details below:

Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates

Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Utility in Parkinson's Disease and Gaucher Disease Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Utility in Parkinson's Disease and Gaucher Disease

News for Gain Therapeutics Stock (GANX)